Unknown

Dataset Information

0

HENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients.

ABSTRACT:

SUBMITTER: Meijer LL 

PROVIDER: S-EPMC5153344 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients.

Meijer Laura L LL   Puik Jisce R JR   Peters Godefridus J GJ   Kazemier Geert G   Giovannetti Elisa E  

The oncologist 20161102 12

Similar Datasets

Unknown Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients.
| S-EPMC4861359 | biostudies-literature
Unknown The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients.
| S-EPMC9020757 | biostudies-literature
Unknown DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
| S-EPMC5104892 | biostudies-literature
Unknown Real-world outcomes of adjuvant gemcitabine <i>versus</i> gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma.
| S-EPMC9092583 | biostudies-literature
Unknown Role of adjuvant (chemo)radiotherapy for resected extrahepatic cholangiocarcinoma: a meta-analysis.
| S-EPMC7383326 | biostudies-literature
Unknown Identifying a unique chromosomal pattern to predict the gemcitabine response in patients with cholangiocarcinoma.
| S-EPMC11978821 | biostudies-literature
Unknown Intratumoural expression of dihydropyrimidine dehydrogenase is an independent prognostic factor in resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine.
| S-EPMC11656693 | biostudies-literature
Unknown PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome.
| S-EPMC7686719 | biostudies-literature
Unknown Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
| S-EPMC6199735 | biostudies-literature
Unknown Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer.
| S-EPMC9990191 | biostudies-literature